Facts and figures

HeadquarterDenmark
InternationalInternational production facilities in seven countries.
Affiliates or offices in 75 countries.
WorkforceApproximately 40,000 employees (March 2014).
Approximately 42% of employees are located in Denmark (16,677) and 58% in the rest of the world (North America: 6,545, Japan & Korea: 1,083, China: 4,958, International Operations: 6,366, Europe: 4,428).
18% within research and development
27% in production and production administration
37% in international sales and marketing
18% in administration
Product areas We have four product areas:
Diabetes care 
Haemostasis management (NovoSeven®) 
Growth hormone therapy 
Hormone replacement therapy (HRT)

According to applicable law, only health care professionals are allowed to access the product information on our site. You can find the information under the Health Care Processionals in the top menu. For patient and disease information, look under Patients. 
Q1 sales*20,343
Annual sales**83,572 (See Annual Report for more information)
Sales by business segment* Diabetes care 15,959
Biopharmaceuticals 4,384
Sales by region* Europe 4,703
North America 9,265
International Operations 3,032
China 2,171
Japan & Korea 1,172

Notes
* million Danish kroner, Q1 results 2014
** million Danish kroner, full year results 2013

Novo Nordisk A/S
Bagsv√¶rd, Denmark, 
CVR nr. 24 25 67 90

  •  


  •  
  •  

Share information

Learn more about Novo Nordisk shares.

Shareholder rights


  •  
  •  

Novo Nordisk products

Facts about Novo Nordisk products

Product facts

  •